| Losartan | Valsartan | Irbesartan | Candesartan | Telmisartan | Olmesartan |
---|---|---|---|---|---|---|
Exposed person-days | 160,956,721 | 252,964,999 | 115,243,240 | 44,349,122 | 46,800,437 | 26,163,756 |
Mean follow-up days | 1263.57 | 1378.66 | 1425.48 | 1124.76 | 1336.51 | 992.22 |
Mean treatment duration (days) | 312.03 | 349.32 | 379.50 | 344.67 | 329.76 | 271.00 |
Mean daily dosage (DDD) | 0.36 | 0.39 | 0.39 | 0.41 | 0.42 | 0.37 |
Number of newly diagnosed diabetes | 16,227 | 25,849 | 11,436 | 4,371 | 4,666 | 2,809 |
Crude incidence rate per 1,000,000 person-days (95% CI) | 100.82 (99.26-102.37) | 102.18 (100.94-103.43) | 99.23 (97.41-101.05) | 98.56 (95.64-101.48) | 99.70 (96.84-102.56) | 107.36 (103.39-111.33) |